Yazar "Temiz, Selami A." seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Cutaneous manifestation of COVID-19 reporting from Middle-Eastern countries: A point of view!
    (Wiley, 2020) Abdelmaksoud, Ayman; Shakshouk, Hadir; Goldust, Mohamad; Dursun, Recep; Temiz, Selami A.; Vestita, Michelangelo
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Erythema Multiforme Associated With Phenytoin and Cranial RadiationTherapy (EMPACT) Syndrome Associated With Cranial Radiotherapy and Levetiracetam: A Case Report
    (Cureus Inc, 2022) Yilmaz, Tugba; Yavuz, Berrin B.; Kanyilmaz, Gul; Aktan, Meryem; Temiz, Selami A.
    Cranial radiotherapy (RT) is an irradiated way to treat patients with brain malignancies. Seizure is the most common symptom. Due to the frequency of seizure risk, cranial RT is usually received concomitant with previously initiated antiepileptic drugs (AED). This combination can lead to erythema multiforme (EM) like serious skin reactions starting from the irradiated port site and spreading to whole cutaneous surfaces and mucosal membranes. This clinical entity is named after as an acronym of components which are Erythema Multiforme associated with Phenytoin And Cranial RadiationTherapy as EMPACT syndrome. Most cases of EMPACT syndrome are reported with phenytoin in the literature, but there are no reported cases with levetiracetam to the best of our knowledge in the literature. Here, we report a 62-year-old male with glioblastoma, presented with severe conjunctivitis, extensive bleeding erosions in his oral mucosa and erythematous macular eruptions on the right temporoparietal port region of the scalp, and EM-like generalized lesions involved neck, chest, back, and arms following the end of his cranial RT. He was diagnosed with EMPACT syndrome, related to using levetiracetam concomitant with cranial RT. Early diagnosis is crucial for the complete response of treatment. Physicians should be alert to possible skin and mucosal reactions of patients under levetiracetam treatment, especially co-existing use of cranial RT.
  • Küçük Resim Yok
    Öğe
    Is prenatal testosterone-estrogen balance associated with psoriasis?
    (Wiley, 2020) Ozer, Ilkay; Temiz, Selami A.; Ataseven, Arzu; Dursun, Recep; Uyar, Mehmet; Ozer, Mustafa
    The etiopathogenesis of psoriasis is not understood; however, psoriasis is affected by hormones, particularly the sex steroids. The second-to-fourth digit (2D:4D) ratio, which is an indicator of prenatal sex hormone balance, has been studied in various diseases that are affected by hormones. A total of 369 individuals comprising 172 patients with psoriasis and 197 healthy volunteers were included in the study. Patients with psoriasis were divided into type-1 and type-2, according to age of onset and family history. The 2D:4D ratio of both hands was recorded for all participants. Females in the psoriasis group had a lower 2D:4D ratio in both hands compared with those in the control group, with no significant difference. Males in the psoriasis group had a higher 2D:4D ratio for both hands compared with those in the control group (P= .009 andP < .001 for the right and left hands, respectively). Further, male patients with type-1 psoriasis had a lower 2D:4D ratio compared to those with type-2 psoriasis. Our results suggest that an alteration of the estrogen-testosterone balance due to prenatal testosterone activity is an independent predisposing factor for psoriasis in males.
  • Küçük Resim Yok
    Öğe
    Isotretinoin and pregnancy termination: an overview
    (Wiley, 2023) Abdelmaksoud, Ayman; Wollina, Uwe; Lotti, Torello; Temiz, Selami A.
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Management of patients with Behcet's disease during theCOVID-19 pandemic
    (Wiley, 2020) Dursun, Recep; Temiz, Selami A.; Ozer, Ilkay; Daye, Munise; Ataseven, Arzu
    Behcet's disease is a disease characterized by chronic inflammatory vasculitis. In the clinical symptoms of Behcet's disease, many immunosuppressive and immunomodulatory drugs are used. The suspicion that drugs used in chronic disease treatments such as Behcet's disease during pandemic will increase the risk of transmission of COVID-19 disease, and that the disease may progress more lethally in these patients after the infection caused clinicians to worry. As far as we know, there is no study in the literature about the management of patients with Behcet's disease in the pandemic period. Fifty-four patients with Behcet's disease who were admitted to the dermatology outpatient clinic between 11 March and July 14, 2020 were retrospectively analyzed. In this pandemic period, 44 of 54 patients were recommended to continue their previous treatment. While the dose of medication used by 7 patients was reduced, it was decided to change the treatment of 3 patients. No life-threatening activation was observed. None of the patients developed COVID-19 disease. This article is important in terms of being the first study in the literature examining the treatment of patients with Behcet's disease during the COVID-19. In this period, we know that the treatment practices in chronic diseases change frequently daily, and in this respect, we hope that our study will provide a perspective to other dermatology clinics in terms of the treatment of Behcet's disease during the pandemic.